Cadila Healthcare secures USFDA approval for Potassium Citrate ER Tablet

From USFDA

Cadila Healthcare announced that Zydus Cadila has received the final approval from the USFDA to market Potassium Citrate ER Tablet 5, 10 and 15 mRq, used in prevention of kidney stones.

The group now has 94 approvals and has so far filed 239 ANDAs since the commencement of the filling process in FY 2003-04.

Powered by Capital Market - Live News